資源 » 參考數據庫 » 客戶發表文獻

至今，GenScript的服務及產品已被Cell, Nature, Science, PNAS等1300多家生物醫藥類雜志引用近萬次，處于行業領先水平。NIH、哈佛、耶魯、斯坦福、普林斯頓、杜克大學等約400家全球著名機構使用GenScript的基因合成、多肽服務、抗體服務和蛋白服務等成功地發表科研成果，再次證明GenScript 有能力幫助業內科學家Make research easy.

Potential limits of AAV-based gene therapy with the use of new transgenes expressing factor IX fusion proteins.

Haemophilia. 2019-01;

Le QuellecSandra, DaneAllison, EnjolrasNathalie, McIntoshJenny, RosalesCecilia, NegrierClaude, Nathwani

Products/Services Used	Details	Operation
Codon Optimization	… vector containing 201 bp of the 3' end of humanly codon‐optimised hFIX (hFIXco) cDNA sequence followed by full linker and mature albumin cDNA sequences, flanked by EcoNI and NheI restriction sites were synthesized (GenScript Biotech Corp., Nanjing, China) and cloned …	Get A Quote

摘要

The variety of treatment for haemophilia B (HB) has recently improved with the emergence of both AAV-based gene therapy and bioengineered human factor IX (hFIX) molecules with prolonged half-life due to fusion to either albumin (Alb) or immunoglobulin Fc fragment (Fc).